The Canadian Journal of Psychiatry,
Год журнала:
2021,
Номер
67(4), С. 260 - 268
Опубликована: Март 1, 2021
Objective:
With
the
increasing
prevalence
of
cannabis
use,
there
is
a
growing
concern
about
its
association
with
depression
and
suicidality.
The
aim
this
study
was
to
examine
relationship
between
recent
use
suicidal
ideation
using
nationally
representative
data
set.
Methods:
A
cross-sectional
analysis
adults
undertaken
National
Health
Nutrition
Examination
Survey
from
2005
2018.
Participants
were
dichotomized
by
whether
or
not
they
had
used
in
past
30
days.
primary
outcome
ideation,
secondary
outcomes
having
recently
seen
mental
health
professional.
Multiple
logistic
regression
adjust
for
potential
confounders,
survey
sample
weights
considered
model.
Results:
Compared
those
no
(
n
=
18,599),
users
3,127)
more
likely
have
experienced
2
weeks
(adjusted
odds
ratio
[aOR]
1.54,
95%
CI,
1.19
2.00,
P
0.001),
be
depressed
(aOR
1.53,
1.29
1.82,
<
professional
12
months
1.28,
1.04
1.59,
0.023).
Conclusions:
Cannabis
days
associated
thinking
adults.
This
multifactorial
but
highlights
need
specific
guidelines
policies
prescription
medical
psychiatric
therapy.
Future
research
should
continue
characterize
effects
general
population.
Pharmacology,
Год журнала:
2022,
Номер
107(3-4), С. 131 - 149
Опубликована: Янв. 1, 2022
<b><i>Background:</i></b>
There
is
a
growing
interest
in
the
use
of
cannabis
(and
its
extracts),
as
well
CBD
oil
(hemp
extracts
containing
cannabidiol),
for
therapeutic
purposes.
While
there
reason
to
believe
that
cannabinoids
may
be
efficacious
number
different
diseases
and
syndromes,
exist
limited
objective
data
supporting
crude
materials
(CBD
oil,
extracts,
and/or
itself).
<b><i>Summary:</i></b>
In
present
review,
we
examined
pure
cannabinoid
compounds
(dronabinol,
nabilone,
CBD),
partially
purified
medicinal
(nabiximols),
provide
guidance
on
potential
uses
high-THC
oil.
general,
support
role
cannabis/cannabinoids
pain,
seizure
disorders,
appetite
stimulation,
muscle
spasticity,
treatment
nausea/vomiting.
Given
biological
activities
cannabinoids,
utility
central
nervous
system
disorders
(such
neurodegenerative
diseases,
PTSD,
addiction)
or
cancer.
However,
those
are
much
less
compelling.
<b><i>Key
Message:</i></b>
On
balance,
reasons
medical
extract
(Δ<sup>9</sup>-THC-dominant
CBD-dominant),
but
more
careful
research
required.
Pharmaceuticals,
Год журнала:
2023,
Номер
16(2), С. 148 - 148
Опубликована: Янв. 19, 2023
The
endocannabinoid
system
(eCB)
has
been
studied
to
identify
the
molecular
structures
present
in
Cannabis
sativa.
eCB
consists
of
cannabinoid
receptors,
endogenous
ligands,
and
associated
enzymatic
apparatus
responsible
for
maintaining
energy
homeostasis
cognitive
processes.
Several
physiological
effects
cannabinoids
are
exerted
through
interactions
with
various
such
as
CB1
CB2
vanilloid
recently
discovered
G-protein-coupled
receptors
(GPR55,
GPR3,
GPR6,
GPR12,
GPR19).
Anandamide
(AEA)
2-arachidoylglycerol
(2-AG),
two
small
lipids
derived
from
arachidonic
acid,
showed
high-affinity
binding
both
receptors.
plays
a
critical
role
chronic
pain
mood
disorders
extensively
because
its
wide
therapeutic
potential
it
is
promising
target
development
new
drugs.
Phytocannabinoids
synthetic
have
shown
varied
affinities
relevant
treatment
several
neurological
diseases.
This
review
provides
description
components
discusses
how
phytocannabinoids
other
exogenous
compounds
may
regulate
balance.
Furthermore,
we
show
hypo-
or
hyperfunctionality
body
related
disorders,
even
integrative
complementary
health
practices
(ICHP)
harmonizing
eCB.
European Archives of Psychiatry and Clinical Neuroscience,
Год журнала:
2024,
Номер
unknown
Опубликована: Сен. 19, 2024
Abstract
The
legalization
of
cannabis
for
medical
and
recreational
purposes
has
progressed
internationally.
Cannabis
cannabinoids
are
advocated
a
plethora
indications.
An
increasing
number
nonmedical
users
regularly
consume
large
doses
delta-9-Tetrahydrocannabinol
(THC),
the
main
active
component
cannabis.
Aim:
to
summarize
evidence
on
(1)
risks
use
(2)
effectiveness
safety
medicinal
Findings
use:
is
mostly
used
experience
its
acute
rewarding
effects.
Regular
high
THC
products
can
produce
addiction
(cannabis
disorder
or
CUD).
Acute
consumption
(including
unintentionally)
cause
time-limited
mental,
gastrointestinal,
cardiovascular
problems
motor
vehicle
accidents.
Chronic
patterns
have
been
associated
with
multiple
adverse
outcomes
that
particular
concern
among
adolescents
young
adults,
such
as,
disrupted
learning,
impaired
cognitive
performance,
reduced
educational
attainment
an
increased
risk
CUD,
psychosis/schizophrenia,
mood
anxiety
disorders
suicidal
behaviors.
There
debate
about
extent
which
these
outcomes.
Physical
health
(e.g.,
respiratory
cardiovascular,
prematurity
restricted
fetal
growth,
hyperemesis
syndrome
others)
also
linked
repeated
content.
Herbal
cannabis,
medicines
from
extracted
synthetized
cannabinoids—often
as
adjuvants
standard
medicines—may
small
modest
benefits.
This
primarily
case
in
treating
chronic
pain,
muscle
spasticity,
chemotherapy-induced
nausea
vomiting,
refractory
epilepsy
(in
cannabidiol,
CBD).
inconclusive
their
value
mental
other
conditions.
Safety:
Cannabis-based
medicine
generally
well
tolerated.
mild
moderate
effects
CUD.
Frontiers in Public Health,
Год журнала:
2024,
Номер
11
Опубликована: Янв. 5, 2024
Background
There
are
well-established
literatures
documenting
the
associations
between
mental
disorders
and
unhealthy
behaviors
such
as
poor
diet
quality,
sedentary
behavior,
cannabis
tobacco
use.
Few
studies
have
attempted
to
understand
respective
findings
in
light
of
each
other,
however.
Objective
The
purpose
this
review
was
assemble
comparable
data
for
behavior-disorder
association
assess
terms
their
overall
strength.
aimed
include
a
representative,
but
not
exhaustive,
range
that
would
allow
explorative
comparisons.
Methods
Eligible
were
identified
via
Pubmed
searches
citation
searching,
restricted
publications
no
older
than
2015
written
English.
To
obtain
data,
only
reported
odds
ratios
included,
risk
bias
related
study
samples,
behavioral
measurement
disparities,
control
variables
assessed
sensitivity
analyses.
Findings
disorder
compared
on
basis
different
measures
central
tendency.
Results
From
3,682
records,
294
included.
found
evidence
four
psychosis,
depression,
anxiety,
bipolar
disorder,
attention-deficit/hyperactivity
(ADHD),
post-traumatic
stress
(PTSD),
while
personality
investigated
relation
In
comparison,
generally
similar
strength,
use
exceptional
being
significantly
stronger
its
counterparts
across
behaviors.
Analyses
some
influence
from
disparities
lack
adequate
statistical
control,
robust
Conclusion
This
comparative
about
equally
strongly
associated
with
disorders.
Given
general
nature
these
associations,
we
should
probably
them
reflect
shared
etiology.
However,
be
regarded
tentative
until
confirmed
by
more
comprehensive
investigations.
Pharmacopsychiatry,
Год журнала:
2024,
Номер
57(03), С. 104 - 114
Опубликована: Март 1, 2024
Abstract
Although
an
increasing
number
of
patients
suffering
from
mental
illnesses
self-medicate
with
cannabis,
current
knowledge
about
the
efficacy
and
safety
cannabis-based
medicine
in
psychiatry
is
still
extremely
limited.
So
far,
no
finished
product
has
been
approved
for
treatment
a
illness.
There
evidence
that
cannabinoids
may
improve
symptoms
autism
spectrum
disorder
(ASD),
Tourette
syndrome
(TS),
anxiety
disorders,
post-traumatic
stress
(PTSD).
According
to
surveys,
often
use
mood,
sleep,
attention
deficit/hyperactivity
(ADHD).
suggesting
tetrahydrocannabinol
(THC)
THC-containing
cannabis
extracts,
such
as
nabiximols,
can
be
used
substitutes
disorder.
Preliminary
also
suggests
involvement
endocannabinoid
system
(ECS)
pathophysiology
TS,
ADHD,
PTSD.
Since
ECS
most
important
neuromodulatory
brain,
it
possibly
induces
beneficial
effects
by
alterations
other
neurotransmitter
systems.
Finally,
management
system.
Thus,
reducing
stress.
Practically,
psychiatric
disorders
does
not
differ
indications.
The
starting
dose
products
should
low
(1–2.5
mg
THC/day),
up-titrated
slowly
(by
1–2.5
every
3–5
days).
average
daily
10–20
THC.
In
contrast,
cannabidiol
(CBD)
mainly
high
doses>400
mg/day.
JAMA Pediatrics,
Год журнала:
2021,
Номер
175(4), С. 377 - 377
Опубликована: Янв. 19, 2021
Cannabis
use
and
cannabis
disorder
(CUD)
are
common
among
youths
young
adults
with
mood
disorders,
but
the
association
of
CUD
self-harm,
suicide,
overall
mortality
risk
is
poorly
understood
in
this
already
vulnerable
population.To
examine
associations
disorders.A
population-based
retrospective
cohort
study
was
performed
using
Ohio
Medicaid
claims
data
linked
death
certificate
data.
The
analysis
included
204
780
(aged
10-24
years)
a
diagnosis
disorders
between
July
1,
2010,
December
31,
2017,
who
were
followed
up
to
365
days
from
index
diagnostic
claim
until
end
enrollment,
self-harm
event,
or
death.
Statistical
April
4
17,
2020.Physician-diagnosed
defined
outpatient
inpatient
180
prior
through
365-day
follow-up
period.Nonfatal
all-cause
mortality,
deaths
by
unintentional
overdose,
motor
vehicle
crashes,
homicide.
Marginal
structural
models
inverse
probability
weights
examined
outcomes.This
(133
081
female
participants
[65.0%];
mean
[SD]
age
at
time
diagnosis,
17.2
[4.10]
years).
documented
for
10.3%
(n
=
21
040)
significantly
associated
older
(14-18
years
vs
10-13
years:
adjusted
ratio
[ARR],
9.35;
95%
CI,
8.57-10.19;
19-24
ARR,
11.22;
10.27-12.26),
male
sex
(ARR,
1.79;
1.74-1.84),
Black
race
1.39;
1.35-1.44),
bipolar
other
(bipolar
disorders:
1.24;
1.21-1.29;
1.20;
1.15-1.25),
history
1.66;
1.52-1.82),
previous
mental
health
visits
1.26;
1.22-1.30),
psychiatric
hospitalizations
1.57-1.76),
emergency
department
1.54;
1.47-1.61).
nonfatal
(adjusted
hazard
[AHR],
3.28;
2.55-4.22)
(AHR,
1.59;
1.13-2.24),
including
overdose
2.40;
1.39-4.16)
homicide
3.23;
1.22-8.59).
Although
suicide
unadjusted
model,
it
not
models.Cannabis
comorbidity
marker
disorders.
These
findings
should
be
considered
as
states
contemplate
legalizing
medical
recreational
marijuana,
both
which
increased
CUD.
